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A B S T R A C T
Electrical storm (ES) is defined as three or more episodes of ventricular fibrillation (VF) or ventricular tachy-
cardia (VT) within 24 h and is associated with an increased cardiac and all-cause mortality. ES is a full ar-
rhythmic emergency, its prevalence steadily increasing along with the number of implantable cardioverter-
defibrillator implanted every year in developed countries. Nowadays, little evidence exists regarding clinical
predictors of ES and their potential association on mortality and heart failure (HF), nor optimal pharmacological
and non-pharmacological treatment has ever been codified. The intErnationaL eLeCTRicAl storm registry
(ELECTRA) is a multicentre, observational, prospective clinical study with two major aims. First, to create an
international database on ES encompassing clinical features, pharmacological management, and interventional
treatment strategies. Second, to describe mortality and rehospitalization rates in patients with ES over a long
follow-up. The primary endpoint is all-cause mortality 3 years after the ES index event. The main secondary
endpoint is hospitalization for all causes 3 years after the ES index event. Other secondary endpoints includes ES
recurrences, unclustered VTs/VFs recurrences, and hospitalizations for HF worsening. A minimum of 500 pa-
tients will be included in the registry, and all patients will be followed-up for a minimum of three years. The
present paper describes the background and current rationale of the ELECTRA study and details the study design,
from enrolment strategy to data collection methods to planned data analysis. A brief overview of the expected
results and their potential clinical and research implications will also be presented (NCT02882139).
1. Introduction
Ventricular arrhythmias such as ventricular tachycardia (VT) and
ventricular fibrillation (VF) represent a major event in the clinical
history of a patient and usually lead to hemodynamic instability and
sudden cardiac death (SCD). Organized ventricular arrhythmias may be
associated with structural heart disease, genetic arrhythmic syndromes
or metabolic disorders [1]. In patients at high risk for ventricular ar-
rhythmias, the guidelines of the European Society of Cardiology sug-
gests the use of an implantable cardioverter-defibrillator (ICD), a sub-
cutaneous device that can quickly recognize and treat ventricular
arrhythmias using fast ventricular pacing (ATP) or direct-current shock
[2].
Recurrences of ventricular arrhythmias and electrical instability
have exponentially increased in the last decades and a new clinical
entity called electrical storm (ES) has risen as a major morbidity and
mortality factor [3]. ES is usually defined as the occurrence of three or
more episodes of VTs/VFs within 24 h requiring either anti-tachycardia
pacing (ATP) or cardioversion/defibrillation [4]. Most of the patients
presenting with ES are in fact already implanted with an ICD. This is
due to three factors. First, as reported before, patients with an ICD have
a higher risk to develop ventricular arrhythmias [5]. Second, the ICD is
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able to treat brief and asymptomatic arrhythmic episodes that would
not be detected by the patient. Third, and more important, the ICD
enables the patient to survive the first arrhythmic episode, making it
possible for the patient to experience further VTs/VFs.
The incidence of ES is debated in different studies and ranges from 4
to 7% in primary prevention and from 10 to 60% in secondary pre-
vention [5]. Despite the wealth of data currently available, there are
still grey areas regarding predictors and optimal treatment, mostly due
to the small samples of the studies available so far [6]. Nonetheless,
almost all authors agree in considering ES an independent predictor of
poor outcome [7]. More recently, the interest has also shifted towards
non patient-related variables as potential predictors of ES. In this con-
text, the MADIT-RIT trial has showed that restricting ICD intervention
to longer or faster arrhythmias is safe and may reduce patient morbidity
and mortality [8], and a multicentre, patient-level meta-analysis has
recently demonstrated that ES presents a higher incidence during
daytime hours and working days, and is associated with an increase in
monthly temperature variation [9].
The aim of the intErnationaL eLeCTRicAl storm registry (ELECTRA)
registry is twofold. First, we want to create an international registry on
ES encompassing clinical features, pharmacological management, and
interventional treatment strategies. Second, we plan to use the data
derived from the registry to describe mortality and rehospitalization
rates in patients with ES over a long follow-up.
2. Methods
2.1. Study design
The ELECTRA is a multicentre, observational, prospective clinical
study aimed at gathering information on a wide cohort of patients af-
fected by ES. Enrolment started on August 1st, 2016 and will continue
for a minimum of three years. There is no pre-specified date for the end
of enrolment, which will continue according to the enrolment rate. A
minimum of 500 patients will be included in the present registry, and
each patient will be followed-up for a minimum of three years. The
exploratory nature intrinsic to the registry characteristics does not
allow a sample size calculation (see Statistical analysis below). However,
the sample size was selected on the estimated enrolment rates of the
participating centres during a 3-year enrolment period. Moreover, the
sample size will be large enough to postulate specific subgroup ana-
lyses.
The inclusion criteria are:
•Diagnosis of ES, defined as three or more episodes of VTs/VFs
within 24-hour and separated by at least 5 min or documentation of
sustained VT lasted at least 12 h
• age ≥18 years old
• written informed consent
The exclusion criteria are few, and aimed to gather a representative
sample of the “real-world” population:
• No ICD implantation
• confirmed or suspected use of drugs or narcotics with known direct
pro-arrhythmic effect
• inability to express an informed consent for the study
All patients admitted to the participating centres will be evaluated
consecutively by the referent investigators. All patients that meet the
above-described criteria will be included in the registry. The study
complies with the Declaration of Helsinki; it was approved by the ethic
committee of each participating center, and was registered into www.
clinicaltrials.gov (NCT02882139). At enrolment, each patient will be
informed on the aim and the design of the study. It will be stated to
each patient that his participation to the registry is voluntary, free and
that the consent can be withdrawn at any time and for any reason. All
patients will be informed to the results of the study through their en-
rolling centres.
2.2. Data collection
All data requested will be collected by the referent investigators at
enrolment and during each follow-up visit. Considering that the ICD
records all the major arrhythmic events since implantation, patients
experiencing an ES previous to the enrolment start can be included
retrospectively if they meet the following additional inclusion criteria:
• Availability of complete and accurate clinical data
• No ICD replacement after the index event, leading to the loss of
original data
• Availability of ECG and echocardiography done for routine clinical
purposes
• Agreement to subscribe the informed consent during the next rou-
tine visit
Data are saved on a dedicated website in agreement with the Italian
regulations on the treatment of personal data. Electronic cards of data
collection transmitted to the study responsible are identified by an al-
phanumeric code. The list of matches between subjects' data and these
codes will be created and kept by local investigators only. The complete
list of all collected variables is shown in Supplementary Table 1. Each
centre will be asked to report every death and hospital admission of all
patients and their causes. Moreover, data about subjects' vital status
will be updated every 6 months, either by telephone call or by ambu-
latory visit.
Collected data will be processed, analysed and reported according
the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) Initiative international guidelines [10].
2.3. Statistical analysis
The primary endpoint will be estimated annually and it will be
expressed as absolute and relative numbers. Survival curves free from
study endpoint, eventually adjusted according to variables of interest
such as gender, age, underlying heart disease, comorbidities and pro-
gramming mode will be calculated according to the Kaplan-Meier
method and compared by Log-rank test for primary and secondary
endpoints. Primary endpoint subgroup analyses for each of the afore-
mentioned variables will be performed too. According to the number of
centres involved, we expect to recruit at least 500 patients. Considering
an annual incidence of the primary endpoint (death from all causes) of
11% according to our experience [7], we expect about 55 deaths at 1-
year follow-up and about 165 deaths at the end of the 3-year follow-up.
The statistical analysis will be conducted using the SPSS 21.0 for
Windows software (SPSS Inc. Chicago, IL, USA). Every test will be two-
tailed and a value of p > 0.05 will be considered significant. Multi-
plicity between the different endpoints will be controlled by the step-
wise Holm procedure.
2.4. Expected results
The primary endpoint of the ELECTRA registry will be all-cause
mortality 3 years after the ES index event. The main secondary end-
point will be hospitalization for all causes 3 years after the ES index
event. Survival and new hospitalizations will be documented through
ICD remote monitoring, internal database checking, and direct phone
interview. Deaths will be classified according to a modified Hinkle-
Thaler classification [11] and categorized into three predefined groups:
sudden death, non-sudden death for cardiovascular causes, and death
for other causes. Non-sudden death for cardiovascular causes will be
divided into HF-related death, coronary death, and death for other
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cardiovascular causes. Other secondary endpoints will be: number of ES
recurrences and time to first recurrence; number of unclustered VTs/
VFs recurrences and time to first recurrence; number of hospitalizations
for HF worsening and time to first HF-related hospitalization.
The final report will also include the following data:
• Prevalence of cardiovascular risk factors (arterial hypertension,
diabetes mellitus, prior stroke or TIA, atrial fibrillation, coronary
artery disease, peripheral vascular disease)
• Concomitant pharmacological therapy at the time of the index event
• Acute and chronic pharmacological management
• Non-pharmacological therapy, including catheter ablation [12,13]
and sympathetic denervation [14].
• Centrality and dispersion measures regarding laboratory, echo-
cardiograph, and electrophysiological parameters
• Centrality and dispersion measures regarding ES inherent variables,




The ELECTRA registry aims to give a solid answer to many open
questions. The first is to estimate with good precision the incidence of
death and cardiovascular events after ES over a long follow-up. The
large sample size will help in define the impact that ES has on overall
survival, and whether ES patients experience more frequently non-
sudden cardiac death and HF-related cardiovascular events, as postu-
lated before [7,15]. In fact, recent evidence links ES and HF quite
tightly, supporting the notion that, in patients with structural heart
disease, ES could be considered among the plethora of HF-related signs
and symptoms rather than an innocent bystander [16].
Second, the present registry will delineate which baseline char-
acteristics are more commonly associated with ES. While clinical pre-
dictors for ES such as secondary prevention, monomorphic VT, reduced
EF, and concomitant therapy with class I anti-arrhythmic drugs are
already known, these data mostly come from retrospective studies
[6,15,17] and meta-analyses [4,5] and still have to be confirmed in a
large, prospective, observational study. Moreover, the ELECTRA will
offer the opportunity to confirm on a larger basis the non-homogeneous
temporal presentation of ES recently postulated by a patient-level meta-
analysis on the subject [9].
Third, data from the ELECTRA registry will define the contemporary
standard of care for ES. The reported prevalence of different pharma-
cological and non-pharmacological treatments will help delineate how
referring centres treat ES nowadays. The ELECTRA will also offer in-
sights on the optimal strategy in ICD programming. A focus on how to
setup the device after the implant is critical, as patients with ES had a
more aggressive ICD, including lower detection rates, shorter detection
times, and no ATP during capacitors charge [18]. Therefore, optimizing
the detection of ventricular arrhythmia could help in reduce ES in-
cidence and its related increased mortality. Data from the present
registry could also become a solid foundation for phase III randomized
clinical trial on non-conventional treatment of ES, such as pharmaco-
logical sedation and sympathetic denervation [14,19].
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